샘플 요청 목록

 카트 문의
시장보고서
상품코드
1533751

세계의 혈액암 치료제 시장

Blood Cancer Therapeutics
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 291 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

혈액암 치료제 세계 시장은 2030년까지 606억 달러에 달할 전망

2023년에 388억 달러로 추정되는 혈액암 치료제 세계 시장은 2030년에는 606억 달러에 이르고, 분석 기간 2023-2030년 CAGR은 6.6%로 성장할 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 만성 골수성 백혈병(CML) 치료제는 CAGR 6.6%로 성장을 지속하고, 분석 기간 종료까지 136억 달러에 달할 것으로 예측됩니다. 급성 림프성 백혈병(ALL) 치료제 부문의 성장률은 분석 기간 동안 CAGR 7.7%로 추정됩니다.

미국 시장은 106억 달러, 중국은 CAGR 10.5%로 성장할 것으로 예측

미국의 혈액암 치료제 시장은 2023년 106억 달러로 추정됩니다. 세계 2위 경제대국인 중국은 2030년까지 131억 달러 규모에 이를 것으로 예측되며 분석 기간 2023-2030년의 CAGR은 10.5%입니다. 다른 주목할만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 2.8%와 6.5%로 예측되고 있습니다. 유럽에서는 독일이 CAGR 4.1%로 성장할 것으로 예측됩니다.

주요 동향과 촉진요인

혈액암은 백혈병, 림프종, 골수종 등 혈액, 골수, 림프계에 영향을 미치는 악성 종양의 광범위한 카테고리를 포함합니다. 혈액암의 치료법은 지난 수십년동안 큰 진보를 이루었는데, 이는 주로 이러한 질환의 유전적·분자적 기반에 대한 이해의 깊어짐에 의한 것입니다. 치료법에는 화학요법, 표적요법, 면역요법, 줄기세포 이식 등이 있어, 각각 혈액암의 유형나 병기에 맞추어 조정되고 있습니다. 예를 들어, 티로신 키나아제 억제제와 같은 표적 요법은 암세포의 증식 경로를 특이적으로 저해함으로써 만성 골수성 백혈병의 치료를 일변시켰습니다. 한편, CAR-T 세포요법과 같은 면역요법은 환자 자신의 면역세포를 재프로그래밍하여 악성세포를 공격시키는 것으로, 일종의 진행된 혈액암의 치료에 눈부신 성공을 나타내고 있습니다.

최근의 혈액암 치료제의 동향에서는 치료 결정의 지침이 되는 유전자 프로파일링과 바이오마커 검사에 초점을 맞춘 맞춤형 의료가 중시되고 있습니다. 이 접근법은 개별 환자에게 가장 효과적인 치료 요법을 확인하는 데 도움이 될뿐만 아니라 부작용의 위험을 최소화 할 수 있습니다. 게다가 이중 특이성 항체나 체크포인트 억제제와 같은 신규약제의 통합은 종양내과의사가 이용할 수 있는 치료수단을 확대하여 내성암이나 재발암 환자에게 새로운 희망을 가져오고 있습니다. 연구가 진행됨에 따라 효능을 높이고 암의 재발 가능성을 줄이는 것을 목표로 하는 멀티모달 치료 전략에서 이러한 첨단 치료법의 병용이 점점 널리 사용되고 있습니다.

혈액암 치료제 시장의 성장은 세계의 혈액암의 이환율 증가, 인구의 고령화, 헬스케어 투자 증가 등, 여러 요인에 의해 초래됩니다. 또한, 보다 효과적이고 독성이 적은 치료법의 선택지로 이어지기 때문에 의약품 개발이나 암 유전체 해석에 있어서의 기술의 진보도 매우 중요합니다. 게다가, 새로운 약물의 조합과 서열을 시험하는 임상시험의 확대가 이 분야의 기술 혁신의 속도를 가속화하고 있습니다. 암 연구에 대한 공적·민간 부문의 자금 원조는 최신의 치료법에 대한 인식과 액세스를 높이기 위한 어드보카시 활동이나 환자 교육 활동과 함께, 중요한 역할을 하고 있습니다. 시장 확대는 획기적인 치료법의 승인 과정을 간소화하고 환자에게 제공을 가속화하는 규제 당국에 의해 더욱 지원되고 있습니다.

조사 대상 기업 예(주목 42사)

  • AbbVie, Inc.
  • Amgen, Inc.
  • Arcellx
  • BeiGene
  • Bristol-Myers Squibb Company
  • Gilead Sciences, Inc.
  • Johnson & Johnson Services, Inc.
  • Karyopharm Therapeutics, Inc.
  • Kite Pharma, Inc.
  • Kura Oncology
  • Novartis International AG
  • Oncolyze Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi SA
  • TScan Therapeutics;

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 기타 중동
  • 아프리카

제4장 경쟁

JHS 24.08.21

Global Blood Cancer Therapeutics Market to Reach US$60.6 Billion by 2030

The global market for Blood Cancer Therapeutics estimated at US$38.8 Billion in the year 2023, is expected to reach US$60.6 Billion by 2030, growing at a CAGR of 6.6% over the analysis period 2023-2030. Chronic Myeloid Leukemia (CML) Therapeutics, one of the segments analyzed in the report, is expected to record a 6.6% CAGR and reach US$13.6 Billion by the end of the analysis period. Growth in the Acute Lymphocytic Leukemia (ALL) Therapeutics segment is estimated at 7.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$10.6 Billion While China is Forecast to Grow at 10.5% CAGR

The Blood Cancer Therapeutics market in the U.S. is estimated at US$10.6 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$13.1 Billion by the year 2030 trailing a CAGR of 10.5% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.8% and 6.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.1% CAGR.

Key Trends and Drivers

Blood cancer encompasses a broad category of malignancies that affect the blood, bone marrow, and lymphatic system, including leukemias, lymphomas, and myeloma. The therapeutic landscape for blood cancers has seen substantial advances over the past few decades, largely driven by a deeper understanding of the genetic and molecular bases of these diseases. Treatment modalities include chemotherapy, targeted therapy, immunotherapy, and stem cell transplantation, each tailored to the specific type of blood cancer and its stage. For instance, targeted therapies such as tyrosine kinase inhibitors have transformed the treatment of chronic myeloid leukemia by specifically inhibiting cancer cell proliferation pathways. Meanwhile, immunotherapies like CAR-T cell therapy have shown remarkable success in treating certain types of advanced blood cancers by reprogramming the patient’s own immune cells to attack malignant cells.

Recent developments in blood cancer therapeutics have emphasized personalized medicine, focusing on genetic profiling and biomarker testing to guide treatment decisions. This approach not only helps in identifying the most effective treatment regimens for individual patients but also minimizes the risk of adverse effects. Furthermore, the integration of novel agents such as bispecific antibodies and checkpoint inhibitors is expanding the therapeutic arsenal available to oncologists, offering new hope to patients with resistant or relapsed cancers. As research continues, the combination of these advanced therapies in multi-modal treatment strategies is increasingly common, aiming to enhance efficacy and reduce the likelihood of cancer recurrence.

The growth in the blood cancer therapeutics market is driven by several factors, including the increasing incidence of blood cancers globally, aging populations, and rising healthcare investments. Technological advancements in drug development and cancer genomics are also pivotal, as they lead to more effective and less toxic treatment options. Moreover, the expansion of clinical trials testing new drug combinations and sequences is accelerating the pace of innovation in this field. Public and private sector funding for cancer research plays a critical role, alongside advocacy and patient education efforts that raise awareness and access to the latest treatments. The market's expansion is further supported by regulatory agencies that are streamlining the approval processes for breakthrough therapies, thereby hastening their availability to patients.

Select Competitors (Total 42 Featured) -

  • AbbVie, Inc.
  • Amgen, Inc.
  • Arcellx
  • BeiGene
  • Bristol-Myers Squibb Company
  • Gilead Sciences, Inc.
  • Johnson & Johnson Services, Inc.
  • Karyopharm Therapeutics, Inc.
  • Kite Pharma, Inc.
  • Kura Oncology
  • Novartis International AG
  • Oncolyze Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi SA
  • TScan Therapeutics;

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Blood Cancer Therapeutics - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Emerging Therapies and Breakthroughs in Blood Cancer Treatment
    • Personalized Medicine and Genetic Testing's Role in Therapy Selection
    • Increasing Global Prevalence of Blood Cancers Driving Research and Development
    • Role of Stem Cell Transplantation in Treatment Protocols
    • Advances in Immunotherapy and Its Market Impact
    • Regulatory Frameworks Facilitating Faster Drug Approvals
    • Patient Advocacy and Access to Experimental Treatments
    • Partnerships between Biotech Firms and Pharmaceutical Giants
    • Impact of Patent Expiries on Generic and Biosimilar Entry
    • Technological Advancements in Drug Delivery Systems
    • Epidemiological Shifts and Their Implications on Demand
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Blood Cancer Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Blood Cancer Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Blood Cancer Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Chronic Myeloid Leukemia (CML) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Chronic Myeloid Leukemia (CML) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Chronic Myeloid Leukemia (CML) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Acute Lymphocytic Leukemia (ALL) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Acute Lymphocytic Leukemia (ALL) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Acute Lymphocytic Leukemia (ALL) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Chronic Lymphocytic Leukemia (CLL) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Chronic Lymphocytic Leukemia (CLL) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Chronic Lymphocytic Leukemia (CLL) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Acute Myeloid Leukemia (AML) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Acute Myeloid Leukemia (AML) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Acute Myeloid Leukemia (AML) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Leukemia Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Leukemia Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Other Leukemia Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Cancer Research Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Cancer Research Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: World 16-Year Perspective for Cancer Research Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Cancer Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Cancer Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: World 16-Year Perspective for Cancer Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Surgical Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Surgical Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: World 16-Year Perspective for Surgical Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: World 16-Year Perspective for Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Blood Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 35: USA Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: USA 16-Year Perspective for Blood Cancer Therapeutics by Leukemia Type - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types for the Years 2014, 2024 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: USA 16-Year Perspective for Blood Cancer Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: Canada 16-Year Perspective for Blood Cancer Therapeutics by Leukemia Type - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types for the Years 2014, 2024 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: Canada 16-Year Perspective for Blood Cancer Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use for the Years 2014, 2024 & 2030
  • JAPAN
    • Blood Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Japan 16-Year Perspective for Blood Cancer Therapeutics by Leukemia Type - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types for the Years 2014, 2024 & 2030
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Japan 16-Year Perspective for Blood Cancer Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use for the Years 2014, 2024 & 2030
  • CHINA
    • Blood Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 53: China Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: China Historic Review for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: China 16-Year Perspective for Blood Cancer Therapeutics by Leukemia Type - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types for the Years 2014, 2024 & 2030
    • TABLE 56: China Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: China Historic Review for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: China 16-Year Perspective for Blood Cancer Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use for the Years 2014, 2024 & 2030
  • EUROPE
    • Blood Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Blood Cancer Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: Europe 16-Year Perspective for Blood Cancer Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Europe Historic Review for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: Europe 16-Year Perspective for Blood Cancer Therapeutics by Leukemia Type - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types for the Years 2014, 2024 & 2030
    • TABLE 65: Europe Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Europe Historic Review for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: Europe 16-Year Perspective for Blood Cancer Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use for the Years 2014, 2024 & 2030
  • FRANCE
    • Blood Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 68: France Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: France Historic Review for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: France 16-Year Perspective for Blood Cancer Therapeutics by Leukemia Type - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types for the Years 2014, 2024 & 2030
    • TABLE 71: France Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: France Historic Review for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: France 16-Year Perspective for Blood Cancer Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use for the Years 2014, 2024 & 2030
  • GERMANY
    • Blood Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 74: Germany Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Germany Historic Review for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Germany 16-Year Perspective for Blood Cancer Therapeutics by Leukemia Type - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types for the Years 2014, 2024 & 2030
    • TABLE 77: Germany Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Germany Historic Review for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Germany 16-Year Perspective for Blood Cancer Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 80: Italy Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Italy Historic Review for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Italy 16-Year Perspective for Blood Cancer Therapeutics by Leukemia Type - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types for the Years 2014, 2024 & 2030
    • TABLE 83: Italy Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Italy Historic Review for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Italy 16-Year Perspective for Blood Cancer Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Blood Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 86: UK Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: UK Historic Review for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: UK 16-Year Perspective for Blood Cancer Therapeutics by Leukemia Type - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types for the Years 2014, 2024 & 2030
    • TABLE 89: UK Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: UK Historic Review for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: UK 16-Year Perspective for Blood Cancer Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 92: Spain Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Spain Historic Review for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Spain 16-Year Perspective for Blood Cancer Therapeutics by Leukemia Type - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types for the Years 2014, 2024 & 2030
    • TABLE 95: Spain Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Spain Historic Review for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Spain 16-Year Perspective for Blood Cancer Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 98: Russia Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Russia Historic Review for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Russia 16-Year Perspective for Blood Cancer Therapeutics by Leukemia Type - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types for the Years 2014, 2024 & 2030
    • TABLE 101: Russia Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Russia Historic Review for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Russia 16-Year Perspective for Blood Cancer Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 104: Rest of Europe Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Rest of Europe Historic Review for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Rest of Europe 16-Year Perspective for Blood Cancer Therapeutics by Leukemia Type - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types for the Years 2014, 2024 & 2030
    • TABLE 107: Rest of Europe Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Rest of Europe Historic Review for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Rest of Europe 16-Year Perspective for Blood Cancer Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Blood Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Blood Cancer Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: Asia-Pacific 16-Year Perspective for Blood Cancer Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 113: Asia-Pacific Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: Asia-Pacific Historic Review for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: Asia-Pacific 16-Year Perspective for Blood Cancer Therapeutics by Leukemia Type - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types for the Years 2014, 2024 & 2030
    • TABLE 116: Asia-Pacific Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: Asia-Pacific Historic Review for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: Asia-Pacific 16-Year Perspective for Blood Cancer Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Blood Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 119: Australia Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: Australia Historic Review for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: Australia 16-Year Perspective for Blood Cancer Therapeutics by Leukemia Type - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types for the Years 2014, 2024 & 2030
    • TABLE 122: Australia Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: Australia Historic Review for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: Australia 16-Year Perspective for Blood Cancer Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use for the Years 2014, 2024 & 2030
  • INDIA
    • Blood Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 125: India Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 126: India Historic Review for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 127: India 16-Year Perspective for Blood Cancer Therapeutics by Leukemia Type - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types for the Years 2014, 2024 & 2030
    • TABLE 128: India Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: India Historic Review for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 130: India 16-Year Perspective for Blood Cancer Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 131: South Korea Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 132: South Korea Historic Review for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 133: South Korea 16-Year Perspective for Blood Cancer Therapeutics by Leukemia Type - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types for the Years 2014, 2024 & 2030
    • TABLE 134: South Korea Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 135: South Korea Historic Review for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 136: South Korea 16-Year Perspective for Blood Cancer Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 137: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Rest of Asia-Pacific Historic Review for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 139: Rest of Asia-Pacific 16-Year Perspective for Blood Cancer Therapeutics by Leukemia Type - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types for the Years 2014, 2024 & 2030
    • TABLE 140: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Rest of Asia-Pacific Historic Review for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 142: Rest of Asia-Pacific 16-Year Perspective for Blood Cancer Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Blood Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Blood Cancer Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 145: Latin America 16-Year Perspective for Blood Cancer Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 146: Latin America Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Latin America Historic Review for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 148: Latin America 16-Year Perspective for Blood Cancer Therapeutics by Leukemia Type - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types for the Years 2014, 2024 & 2030
    • TABLE 149: Latin America Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Latin America Historic Review for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 151: Latin America 16-Year Perspective for Blood Cancer Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 152: Argentina Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Argentina Historic Review for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 154: Argentina 16-Year Perspective for Blood Cancer Therapeutics by Leukemia Type - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types for the Years 2014, 2024 & 2030
    • TABLE 155: Argentina Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Argentina Historic Review for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 157: Argentina 16-Year Perspective for Blood Cancer Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 158: Brazil Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Brazil Historic Review for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 160: Brazil 16-Year Perspective for Blood Cancer Therapeutics by Leukemia Type - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types for the Years 2014, 2024 & 2030
    • TABLE 161: Brazil Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Brazil Historic Review for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 163: Brazil 16-Year Perspective for Blood Cancer Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 164: Mexico Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Mexico Historic Review for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 166: Mexico 16-Year Perspective for Blood Cancer Therapeutics by Leukemia Type - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types for the Years 2014, 2024 & 2030
    • TABLE 167: Mexico Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Mexico Historic Review for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 169: Mexico 16-Year Perspective for Blood Cancer Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 170: Rest of Latin America Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 171: Rest of Latin America Historic Review for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 172: Rest of Latin America 16-Year Perspective for Blood Cancer Therapeutics by Leukemia Type - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types for the Years 2014, 2024 & 2030
    • TABLE 173: Rest of Latin America Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 174: Rest of Latin America Historic Review for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 175: Rest of Latin America 16-Year Perspective for Blood Cancer Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Blood Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Blood Cancer Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 178: Middle East 16-Year Perspective for Blood Cancer Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 179: Middle East Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 180: Middle East Historic Review for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 181: Middle East 16-Year Perspective for Blood Cancer Therapeutics by Leukemia Type - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types for the Years 2014, 2024 & 2030
    • TABLE 182: Middle East Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Middle East Historic Review for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 184: Middle East 16-Year Perspective for Blood Cancer Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 185: Iran Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Iran Historic Review for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 187: Iran 16-Year Perspective for Blood Cancer Therapeutics by Leukemia Type - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types for the Years 2014, 2024 & 2030
    • TABLE 188: Iran Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Iran Historic Review for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 190: Iran 16-Year Perspective for Blood Cancer Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 191: Israel Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 192: Israel Historic Review for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 193: Israel 16-Year Perspective for Blood Cancer Therapeutics by Leukemia Type - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types for the Years 2014, 2024 & 2030
    • TABLE 194: Israel Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 195: Israel Historic Review for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 196: Israel 16-Year Perspective for Blood Cancer Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 197: Saudi Arabia Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 198: Saudi Arabia Historic Review for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 199: Saudi Arabia 16-Year Perspective for Blood Cancer Therapeutics by Leukemia Type - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types for the Years 2014, 2024 & 2030
    • TABLE 200: Saudi Arabia Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 201: Saudi Arabia Historic Review for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 202: Saudi Arabia 16-Year Perspective for Blood Cancer Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 203: UAE Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 204: UAE Historic Review for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 205: UAE 16-Year Perspective for Blood Cancer Therapeutics by Leukemia Type - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types for the Years 2014, 2024 & 2030
    • TABLE 206: UAE Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 207: UAE Historic Review for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 208: UAE 16-Year Perspective for Blood Cancer Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 209: Rest of Middle East Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 210: Rest of Middle East Historic Review for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 211: Rest of Middle East 16-Year Perspective for Blood Cancer Therapeutics by Leukemia Type - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types for the Years 2014, 2024 & 2030
    • TABLE 212: Rest of Middle East Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 213: Rest of Middle East Historic Review for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 214: Rest of Middle East 16-Year Perspective for Blood Cancer Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use for the Years 2014, 2024 & 2030
  • AFRICA
    • Blood Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 215: Africa Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 216: Africa Historic Review for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 217: Africa 16-Year Perspective for Blood Cancer Therapeutics by Leukemia Type - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types for the Years 2014, 2024 & 2030
    • TABLE 218: Africa Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 219: Africa Historic Review for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 220: Africa 16-Year Perspective for Blood Cancer Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use for the Years 2014, 2024 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제